scholarly article | Q13442814 |
P50 | author | Kam M Hui | Q56872772 |
Berwini Endaya | Q59560731 | ||
Ivy A W Ho | Q79316768 | ||
P2093 | author name string | Paula Y P Lam | |
Yulyana Yulyana | |||
Chang M Guo | |||
Wai H Ng | |||
P2860 | cites work | Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway | Q24298796 |
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP | Q24302531 | ||
Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning | Q24303818 | ||
The effects of connexin phosphorylation on gap junctional communication | Q24603834 | ||
Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas | Q24799123 | ||
Carbenoxolone does not cross the blood brain barrier: an HPLC study | Q25256552 | ||
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
Pluripotency of mesenchymal stem cells derived from adult marrow | Q29617959 | ||
Transduction of cell survival signals by connexin-43 hemichannels | Q30167739 | ||
TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo | Q30318545 | ||
Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells | Q33689870 | ||
Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins | Q33780727 | ||
Structural and functional diversity of connexin genes in the mouse and human genome | Q34137753 | ||
Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery | Q35086666 | ||
Defective gap junctional intercellular communication in the carcinogenic process | Q36344542 | ||
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. | Q36731174 | ||
Modulation of osteoblast gap junction connectivity by serum, TNFalpha, and TRAIL. | Q37272243 | ||
The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway | Q37302737 | ||
TRAIL gene therapy: from preclinical development to clinical application | Q37307340 | ||
Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. | Q37341171 | ||
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide | Q37356520 | ||
TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges | Q37370856 | ||
Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. | Q37407113 | ||
Homing Pathways of Mesenchymal Stromal Cells (MSCs) and Their Role in Clinical Applications | Q37788681 | ||
Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation | Q39237066 | ||
Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis | Q39495600 | ||
A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models | Q39630653 | ||
Hybrid herpes simplex virus/Epstein-Barr virus amplicon viral vectors confer enhanced transgene expression in primary human tumors and human bone marrow-derived mesenchymal stem cells. | Q39641577 | ||
Connexin43 inhibits the oncogenic activity of c-Src in C6 glioma cells | Q39672915 | ||
TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. | Q39906154 | ||
Bystander effect in glioblastoma cells with a predominant cytoplasmic localization of connexin43. | Q39965334 | ||
HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells. | Q39974606 | ||
Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells | Q39983699 | ||
Connexin 43 confers resistance to hydrogen peroxide-mediated apoptosis. | Q40087234 | ||
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. | Q40287620 | ||
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer | Q40359028 | ||
Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line | Q40394969 | ||
Inhibition of Connexin 26/43 and Extracellular-Regulated Kinase Protein Plays a Critical Role in Melatonin Facilitated Gap Junctional Intercellular Communication in Hydrogen Peroxide-Treated HaCaT Keratinocyte Cells | Q42404459 | ||
Changes in gap junction organization and decreased coupling during induced apoptosis in lens epithelial and NIH-3T3 cells. | Q42833342 | ||
Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells | Q42874678 | ||
Reversible inhibition of intercellular junctional communication by glycyrrhetinic acid | Q44325495 | ||
LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors | Q45866584 | ||
Gap junctions in human glioblastomas: implications for suicide gene therapy | Q45872003 | ||
Connexin43 is involved in the effect of endothelin-1 on astrocyte proliferation and glucose uptake | Q46404427 | ||
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety | Q46661382 | ||
Glycyrrhetinic acid derivatives: a novel class of inhibitors of gap-junctional intercellular communication. Structure-activity relationships | Q46979453 | ||
Gap-junction blocker carbenoxolone differentially enhances NMDA-induced cell death in hippocampal neurons and astrocytes in co-culture | Q48220479 | ||
Cancer Vaccines in Glioma: How to Balance the Challenges of Small Trials, Efficiency, and Potential Adverse Events | Q53074821 | ||
Inhibition of gap junction-mediated intercellular communication by TNF-alpha in cultured human corneal fibroblasts. | Q54674022 | ||
Mitochondrial connexin43 as a new player in the pathophysiology of myocardial ischaemia-reperfusion injury. | Q55045700 | ||
Mutations in the second extracellular region of connexin 43 prevent localization to the plasma membrane, but do not affect its ability to suppress cell growth. | Q55472714 | ||
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer | Q60620763 | ||
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions | Q73704158 | ||
Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3) | Q79843385 | ||
Carbenoxolone inhibits junctional transfer and upregulates Connexin43 expression by a protein kinase A-dependent pathway | Q82907665 | ||
Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection | Q83896557 | ||
P433 | issue | 13 | |
P304 | page(s) | 1870-1882 | |
P577 | publication date | 2013-03-26 | |
P1433 | published in | Stem Cells and Development | Q15724421 |
P1476 | title | Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma | |
P478 | volume | 22 |
Q90575658 | A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma |
Q94562165 | Cisplatin-induced ototoxicity in organotypic cochlear cultures occurs independent of gap junctional intercellular communication |
Q47770967 | Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications |
Q91986688 | Connexins in cancer: bridging the gap to the clinic |
Q42368059 | Decoy TRAIL receptor CD264: a cell surface marker of cellular aging for human bone marrow-derived mesenchymal stem cells |
Q30657733 | Differential connexin function enhances self-renewal in glioblastoma |
Q90929877 | Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells |
Q47438502 | Downregulation of spinal astrocytic connexin43 leads to upregulation of interleukin-6 and cyclooxygenase-2 and mechanical hypersensitivity in mice. |
Q38139850 | Human mesenchymal stem cells and their paracrine factors for the treatment of brain tumors |
Q92941476 | Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide |
Q47109590 | Mesenchymal stem cells as therapeutic agents and in gene delivery for the treatment of glioma*. |
Q35399206 | Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling |
Q92987374 | Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness |
Q37049935 | Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme. |
Q28076798 | Role of nanotechnology and gene delivery systems in TRAIL-based therapies |
Q90711989 | Survival of aging CD264+ and CD264- populations of human bone marrow mesenchymal stem cells is independent of colony-forming efficiency |
Search more.